SERPINA1 and alpha 1-antitrypsin deficiency: The provision of AAT-specific therapy to patients with this genotype would be dependent on further prospective studies focused on better understanding the natural history of PI*MZ AATD, and studies evaluating the response of PI*MZ individuals to augmentation therapy.